Aripiprazole for the maintenance treatment of bipolar disorder: A review of available evidence

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 319-323

  McIntyre, Roger S ^a,b,c   Yoon, Jinju ^c   Jerrell, Jeanette M ^d   Liauw, Samantha S ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Maintenance; Pharmacology

Indexed keywords

ARIPIPRAZOLE; LAMOTRIGINE; LITHIUM; PLACEBO; VALPROIC ACID;

AKATHISIA; ANXIETY; BIPOLAR I DISORDER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE HYPERTONIA; NAUSEA; NERVOUSNESS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; WEIGHT GAIN;

EID: 80053644793     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S13876     Document Type: Review

References (22)

1. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother. 2007;8(7):1001-1009.
2. Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005;5(3):297-307.
3. Bristol-Myers Squibb Company, Otsuka America Pharmaceutical Inc. Aripirazole Product Monograph. Product Monograph. 10-1-2006.
4. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649-666.
5. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62(12):923-924.
6. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 2003;37(5):687-694.
7. Wood MD, Scott C, Clarke K, et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006;546(1-3):88-94.
8. Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004;1003(1-2):9-17.
9. Tadori Y, Miwa T, Tottori K, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol. 2005;515(1-3):10-19.
10. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, doubleblind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637.
11. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006115.
12. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66 Suppl 3:28-36.
13. Keck PE, et al. 26-Week Aripiprazole vs Placebo Maintenance. J Clin Psychiatry. 2004;67(4):626-637.
14. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
15. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo- controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247-256.
16. Keck PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491.
17. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placeboand lithium-controlled study. J Affect Disord. 2009;112(1-3):36-49.
18. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010;26(6):1485-1496.
19. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008;165(10):1316-1325.
20. Carlson BX, Sun W, Timko K, et al. Efficacy and safety of aripiprazole in combination with lamotrigine in a long-term maintenance study in manic or mixed subjects with bipolar I disorder (CN138-392). Proceedings of the 50th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2010 Jun 14-17; Boca Raton, Florida.
21. Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011;13(2):133-144.
22. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13-20.